(CercleFinance.com) – Roche announced positive long-term follow-up data from a Phase III study in people with early-stage HER2-positive breast cancer (eBC) with residual invasive disease following neoadjuvant treatment (before surgery).
A ‘statistically and clinically significant’ improvement in overall survival (OS), a secondary endpoint, was observed with adjuvant (post-surgical) Kadcyla (trastuzumab emtansine) compared to Herceptin (trastuzumab). Thus, at 7 years, the OS rates were 89.07% and 84.37% for Kadcyla and Herceptin, respectively.
Additionally, Kadcyla reduced the risk of disease recurrence or death from any cause by 46% compared to Herceptin.
“We are excited that Kadcyla can offer people with early HER2-positive breast cancer with a particularly poor prognosis a chance to live longer and without a recurrence of their disease,” said Levi Garraway, MD, Ph.D ., medical director and medical director of Roche.
Copyright (c) 2023 CercleFinance.com. All rights reserved.